This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET


Shokouhi, S., Claassen, D., Kang, H., Ding, Z., Rogers, B., Mishra, A., Riddle, W. R.


Journal Of Nuclear Medicine: Official Publication, Society Of Nuclear Medicine, Volume: 54, No.: 9, Pages.: 1564-1569

Year of Publication



Unlabelled: Evaluating the symptomatic progression of mild cognitive impairment (MCI) caused by Alzheimer disease (AD) is practically accomplished by tracking performance on cognitive tasks, such as the Alzheimer Disease Assessment Scale’s cognitive subscale (ADAS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ). The longitudinal relationships between cognitive decline and metabolic function as assessed using (18)F-FDG PET are needed to address both the cognitive and the biologic progression of disease state in individual subjects. We conducted an exploratory investigation to evaluate longitudinal changes in brain glucose metabolism of individual subjects and their relationship to the subject’s changes of cognitive status.; Methods: We describe a method to determine correlations in (18)F-FDG spatial distribution over time. This parameter is termed the regional (18)F-FDG time correlation coefficient (rFTC). By using linear mixed-effects models, we determined the difference in the rFTC decline rate between controls and subjects at high risk of developing AD, such as individuals with MCI or the presence of apolipoprotein E (APOE)-ε4 allele. The association between each subject’s rFTC and performance on cognitive tests (ADAS_cog, MMSE, and FAQ) was determined with 2 different correlation methods. All subject data were downloaded from the Alzheimer Disease Neuroimaging Initiative.; Results: The rFTC values of controls remained fairly constant over time (-0.003 annual change; 95% confidence interval, -0.010-0.004). In MCI patients, the rFTC declined faster than in controls by an additional annual change of -0.02 (95% confidence interval, -0.030 to -0.010). In MCI patients, the decline in rFTC was associated with cognitive decline (ADAS_cog, P = 0.011; FAQ, P = 0.0016; MMSE, P = 0.004). After a linear effect of time was accounted for, visit-to-visit changes in rFTC correlated with visit-to-visit changes in all 3 cognitive tests.; Conclusion: Longitudinal changes in rFTC detect subtle metabolic changes in individuals associated with variations in their cognition. This analytic tool may be useful for a patient-based monitoring of cognitive decline.;

Bibtex Citation

@article{Shokouhi_2013, doi = {10.2967/jnumed.112.116137}, url = {}, year = 2013, month = {jul}, publisher = {Society of Nuclear Medicine}, volume = {54}, number = {9}, pages = {1564--1569}, author = {S. Shokouhi and D. Claassen and H. Kang and Z. Ding and B. Rogers and A. Mishra and W. R. Riddle}, title = {Longitudinal Progression of Cognitive Decline Correlates with Changes in the Spatial Pattern of Brain 18F-{FDG} {PET}}, journal = {Journal of Nuclear Medicine} }


18ffdg time correlation, aged, aged, 80 and over, aging, alzheimer imaging, brain, diagnostic use, female, fluorodeoxyglucose f18, humans, longitudinal 18ffdg imaging, longitudinal studies, male, metabolism, methods, middle aged, mild cognitive impairment, pharmacokinetics, physiopathology, radionuclide imaging, radiopharmaceuticals, reproducibility of results, sensitivity and specificity, spatiotemporal analysis

Countries of Study


Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Neuroimaging (e.g. MRI, PET, CAT etc.)